Natco Pharma achieves flawless USFDA Inspection

Natco Pharma Limited proudly announces the successful completion of the United States Food and Drug Administration's (USFDA) inspection of its Pharmacovigilance Department. The evaluation, conducted from October 30, 2023, to November 1, 2023, yielded zero observations, affirming Natco's stringent adherence to pharmacovigilance standards.

The inspection encompassed a thorough assessment of Natco's pharmacovigilance procedures for products distributed globally, with a specific focus on the US market. The results affirm that Natco Pharma meets the stringent requirements set forth by the USFDA.

Natco's Corporate Office in Hyderabad was the epicenter of this evaluation, reflecting the company's dedication to maintaining the highest standards in pharmaceutical compliance. This accomplishment underscores Natco Pharma's commitment to ensuring the safety and efficacy of its pharmaceutical products for consumers, both domestically and internationally.